[go: up one dir, main page]

MX2018014129A - Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. - Google Patents

Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Info

Publication number
MX2018014129A
MX2018014129A MX2018014129A MX2018014129A MX2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A MX 2018014129 A MX2018014129 A MX 2018014129A
Authority
MX
Mexico
Prior art keywords
eteplirsen
pharmaceutical composition
subject
administering
treating
Prior art date
Application number
MX2018014129A
Other languages
English (en)
Inventor
Holt Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2018014129A publication Critical patent/MX2018014129A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden Eteplirsen; en la presente también se proporcionan métodos para tratar una enfermedad muscular en un sujeto en necesidad de los mismos, que comprende administrar al sujeto una composición farmacéutica de la descripción.
MX2018014129A 2016-05-24 2017-05-24 Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. MX2018014129A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340947P 2016-05-24 2016-05-24
US201662429160P 2016-12-02 2016-12-02
PCT/US2017/034265 WO2017213854A1 (en) 2016-05-24 2017-05-24 Pharmaceutical composition comprising eteplirsen

Publications (1)

Publication Number Publication Date
MX2018014129A true MX2018014129A (es) 2019-04-29

Family

ID=59093599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014129A MX2018014129A (es) 2016-05-24 2017-05-24 Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.

Country Status (15)

Country Link
US (1) US20190275072A1 (es)
EP (1) EP3463390A1 (es)
JP (1) JP2019516730A (es)
KR (1) KR20190009343A (es)
CN (1) CN109562123A (es)
AU (1) AU2017278699A1 (es)
BR (1) BR112018074299A2 (es)
CA (1) CA3024178A1 (es)
CO (1) CO2018013828A2 (es)
IL (1) IL263040A (es)
MA (1) MA45158A (es)
MX (1) MX2018014129A (es)
SG (1) SG11201809494VA (es)
TW (1) TW201805002A (es)
WO (1) WO2017213854A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
JP2021526796A (ja) * 2018-06-13 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
EP4219717A3 (en) * 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP7579147B2 (ja) * 2018-06-14 2024-11-07 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
EP4665854A1 (en) 2024-01-29 2025-12-24 Arnatar Therapeutics, Inc Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
AU4225889A (en) 1988-09-01 1990-04-02 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
EP3808845A1 (en) 2004-06-28 2021-04-21 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
PL2623507T3 (pl) 2010-09-30 2017-03-31 Nippon Shinyaku Co., Ltd. Pochodna kwasu morfolinonukleinowego
WO2013082551A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN103933549A (zh) * 2013-01-17 2014-07-23 刘海俊 一种新的血管抑素滴眼剂及其制备方法
WO2014144978A2 (en) * 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
WO2017213854A1 (en) 2017-12-14
CA3024178A1 (en) 2017-12-14
JP2019516730A (ja) 2019-06-20
CO2018013828A2 (es) 2018-12-28
SG11201809494VA (en) 2018-12-28
EP3463390A1 (en) 2019-04-10
KR20190009343A (ko) 2019-01-28
IL263040A (en) 2018-12-31
BR112018074299A2 (pt) 2019-03-12
MA45158A (fr) 2019-04-10
CN109562123A (zh) 2019-04-02
US20190275072A1 (en) 2019-09-12
AU2017278699A1 (en) 2018-11-15
TW201805002A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TW201613901A (en) New compounds
MX2018006223A (es) Moduladores de ror-gamma.
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX393568B (es) Profarmacos de carbidopa y l-dopa y metodos de uso
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2019000677A (es) Células miméticas de células b.
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MY203626A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules
WO2015159155A3 (en) Novel ademetionine formulations
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина